Pubblicazioni

Autori:

Guglielmi, Valeria; Nowis, Dominika; Tinelli, Martina; Malatesta, Manuela; Paoli, Laura; Marini, Matteo; Manganotti, Paolo; Sadowski, Radoslaw; Wilczynski, Grzegorz M.; Meneghini, Vittorio; Tomelleri, Giuliano; Vattemi, Gaetano Nicola

Titolo:

Bortezomib-induced muscle toxicity in multiple myeloma

Anno:

2017

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

Journal of Neuropathology and Experimental Neurology

ISSN Rivista:

0022-3069

N° Volume:

76

Numero o Fascicolo:

7

Intervallo pagine:

620-630

Parole chiave:

Bortezomib; metabolic myopathy; multiple myeloma; muscle toxicity; proteasome inhibitors

Breve descrizione dei contenuti:

Multiple myeloma (MM) accounts for ∼13% of all hematologic malignancies. Bortezomib treatment is effective in MM, but can be complicated with neurological side effects. We describe a patient with symptomatic MM who had a reversible metabolic myopathy associated with bortezomib administration and pathologically characterized by excessive storage of lipid droplets together with mitochondrial abnormalities. In a single-center prospective study, 14 out of 24 patients with symptomatic MM were treated with bortezomib and, among these, 7 developed muscular signs and/or symptoms. The myopathy was characterized by a proximal muscle weakness involving lower limbs and was an early complication. Complete resolution of muscle weakness occurred after treatment discontinuation. Conversely, none of the patients who received a treatment without bortezomib developed muscular symptoms. Experimental studies demonstrate that in primary human myoblasts bortezomib at low concentrations leads to excessive storage of lipid droplets together with structural mitochondrial abnormalities, recapitulating the pathologic findings observed in patient's muscle. Our data suggest that patients treated with bortezomib should be monitored for muscular signs and/or symptoms and muscle weakness should alert the clinician to the possibility of myopathy. Bortezomib-induced metabolic myopathy is a potentially reversible entity with important implications for management and treatment of patients with MM.

Pagina Web:

https://doi.org/10.1093/jnen/nlx043

Id prodotto:

98848

Handle IRIS:

11562/968296

ultima modifica:

29 novembre 2022

Citazione bibliografica:

Guglielmi, Valeria; Nowis, Dominika; Tinelli, Martina; Malatesta, Manuela; Paoli, Laura; Marini, Matteo; Manganotti, Paolo; Sadowski, Radoslaw; Wilczynski, Grzegorz M.; Meneghini, Vittorio; Tomelleri, Giuliano; Vattemi, Gaetano Nicola, Bortezomib-induced muscle toxicity in multiple myeloma «Journal of Neuropathology and Experimental Neurology» , vol. 76 , n. 7 , 2017 , pp. 620-630

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo